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Abstract
Background: Between 2007 and 2011, the Netherlands experienced the largest documented Q-fever outbreak to
date with a total of 4108 notified acute Q-fever patients. Previous studies have indicated that Q-fever patients may
suffer from long-lasting health effects, such as fatigue and reduced quality of life. Our study aims to determine the
long-term health impact of Q-fever. It will also compare the health status of Q-fever patients with three reference
groups: 1) healthy controls, 2) patients with Legionnaires’ disease and 3) persons with a Q-fever infection but
a-specific symptoms.
Methods/design: Two groups of Q-fever patients were included in a prospective cohort study. In the first group
the onset of illness was in 2007–2008 and participation was at 12 and 48 months. In the second group the onset of
illness was in 2010–2011 and participation was at 6 time intervals, from 3 to 24 months. The reference groups were
included at only one time interval. The subjective health status, fatigue status and quality of life of patients will be
assessed using two validated quality of life questionnaires.
Discussion: This study is the largest prospective cohort study to date that focuses on the effects of acute Q-fever. It
will determine the long-term (up to 4 years) health impact of Q-fever on patients and compare this to three
different reference groups so that we can present a comprehensive assessment of disease progression over time.
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Background
Q-fever is a zoonosis that is caused by the intracellular
bacterium Coxiella burnetii. A wide variety of animal
species can be infected with the bacterium, including
domesticated animals such as goats, sheep and cows [1].
Q-fever was known as an occupational illness until 2007,
mainly infecting farmers, veterinarians and laboratory
workers. An obligatory notification for Q-fever patients
was introduced in the Netherlands in 1978 and the mean
number of patients was around 17 cases per annum [2].
However, starting in 2007 the number of new patients
increased annually, reaching a total of 4108 notified
acute Q-fever patients over the period 2007–2011, of
which at least 24 persons (0.6%) died [2].
Whilst the number of Q-fever cases has gradually
increased in Europe in recent years, no other country
has experienced an epidemic of this scale and the Dutch
outbreak has become the largest documented outbreak
in the world [3-13]. In comparison, the highest number
of patients reported in an outbreak before 2007 was 415
in Switzerland [5]. Several measures were taken by the
Dutch government in late 2009 to prevent the further
spread of the disease (including the vaccination of goats
and sheep on farms with more than 50 animals, and the
culling of pregnant goats and sheep at farms that were
found to be infected [14]), which has led to a massive
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reduction in the number of new patients since 2010
(there were 74 cases in 2011) [2].
Approximately 40% of all persons infected with Q-fever
develop symptoms such as fever, pneumonia and hepatitis
[5,15]. Several studies have shown that a relatively large
group of patients suffer from persistent fatigue after acute
Q-fever [16-18]. One study showed that the percentage of
patients affected by persistent fatigue declines over time,
ranging from 80% several weeks after infection, to less
than 30% one year after onset of illness [17]. In another
study, 42% of Q-fever patients reported symptoms fulfill-
ing the criteria of Chronic Fatigue Syndrome one year
after onset of illness [16]. This illness is also known as
Post Q-fever Fatigue Syndrome, of which symptoms can
last for as long as 10 years [18]. Among patients with an
acute infection, an estimated 1.9% of patients develop
chronic Q-fever, a potentially life-threatening condition
[19]. Due to the limited number of large outbreaks to date,
data from these studies are often based on a small num-
bers of patients which limits the accuracy and generalis-
ability of the estimates. The current Q-fever outbreak in
the Netherlands offers a unique opportunity to study the
natural history of Q-fever infections, including the long
term health impact, and ECDC has recommended the ini-
tiation of prospective cohort studies to better diagnose
and treat acute Q-fever [19].
A number of studies have been conducted in the
Netherlands that focus on Q-fever patients with an onset
of illness in 2007/2008 and have monitored long-term
symptoms (including fatigue), functional impairment
and quality of life [20,21]. In a case–control study, Limo-
nard et al. found severe fatigue levels in 52% of patients
(N = 54), one year after onset of illness. In a retrospect-
ive study (N = 515), Morroy et al. found that 45% and
44% of patients were severely affected in their quality of
life and fatigue respectively at least one year after they
became ill. Both studies indicate that Q-fever causes ser-
ious long-term health problems. Limitations of these
studies were 1) the health status of patients was only
measured at 12 months after onset of illness, 2) the
healthy control groups were small and not age-matched
to the Q-fever patients, and 3) the health status of Q-fever
patients was not compared to that of patients with an-
other infectious illness [20,21].
Both Limonard et al. and Morroy et al. used the
Nijmegen Clinical Screening Instrument (NCSI) to assess
the health impact of acute Q-fever. This instrument was
published in 2009 and combines a number of different
health questionnaires. It was originally developed as a
screening tool to assess the health status of patients with
Chronic Obstructive Pulmonary Disease (COPD) [22], but
has since been used in Q-fever studies [20,21]. The NCSI
measures eight aspects of health status, covering symp-
toms (including fatigue), functional impairment and
quality of life. Another instrument for measuring quality
of life is the widely used Short Form 36 (SF-36), which
was developed in 1988 by Ware and Stewart for the Me-
dical Outcomes Study, and aims to correctly assess the
quality of life of patients with a limited number of ques-
tions [23]. To our knowledge, the NCSI and SF-36 have
never before been used side by side.
Apart from an Australian study which compared the
long-term health impact of Q-fever patients to the
health impact of patients infected with Epstein-Barr
virus and Ross River virus [17], we have not found any
other study that has compared the health impact of Q-fever
patients to the health impact of patients with another infec-
tious disease. This type of study is important as it can pro-
vide useful information on whether long-term health
effects are specific to a certain infection, or whether they
are common after suffering from any severe infectious ill-
ness. Patients suffering from Legionnaires’ disease were
included as a reference group, as 1) the clinical manifest-
ation of the acute phase of Legionnaires’ disease is similar
to the acute phase of many of the Q-fever patients (almost
all patients with Legionnaires’ disease and many Q-fever
patients suffer from pneumonia), 2) the pathogens causing
Legionnaires’ disease (Legionella pneumophila) and Q-fever
(Coxiella burnetii) belong to the same order of Proteobac-
teria known as Legionellales [24] and 3) there is limited in-
formation on the long-term health impact of Legionnaires’
disease [25-27].
Not everyone who becomes infected with Q-fever
becomes a notifiable Q-fever patient, as the majority of
infected persons suffer from mild symptoms or no
symptoms at all [5]. In this paper, we refer to this group
as being persons with a Q-fever infection but a-specific
symptoms and it is currently unknown whether they
are at risk of developing persistent fatigue or chronic
Q-fever. Our study has therefore included a group of per-
sons with a-specific symptoms as an additional reference
group.
Methods/design
The designs used in this study are:
 a prospective cohort study of Q-fever patients: one
group of patients over a period of 2 years and
another group over a period of 4 years;
 three cross-sectional surveys of healthy controls,
patients with Legionnaires’ disease 12 months after
infection and persons with a Q-fever infection but
a-specific symptoms roughly 4 years after infection.
All patients included in this study lived in the
Netherlands, and were contacted between 2010 and
2013. The study protocol was submitted to the Medical
Ethical Review Board of the Radboud University
van Loenhout et al. BMC Infectious Diseases 2012, 12:280 Page 2 of 6
http://www.biomedcentral.com/1471-2334/12/280
Nijmegen Medical Centre, which indicated that ethical
review was not required as participation consists of fill-
ing out one or more anonymous questionnaires. The
data on the healthy controls were derived from a dif-
ferent study, for which approval was given by the Me-
dical Ethical Review Board of the Radboud University
Nijmegen Medical Centre (reference number: 2006/243).
Figure 1 shows which questionnaires were completed
and at which time interval.
Study population
Patients with Q-fever
Our first cohort group consisted of patients with an
onset of illness in 2007 and 2008 from two Municipal
Health Service regions in the province of Noord-Brabant
who participated in the study of Morroy et al. [21].
Patients from that study who also gave permission to be
included in further research studies were contacted by
our researcher approximately 4 years after onset of ill-
ness. All patients fitted the Dutch notification criteria.
This includes a positive serology by one of the following
laboratory tests:
 Identifying a seroconversion or a quadrupled or
higher increase in IgG antibody titre against C.
burnetti in a paired serum sample (sera obtained in
the acute phase and recovery phase with a time
interval ≥ 2 weeks) by indirect immunofluorescence
or complement fixation test;
 Presence of IgM-antibodies against phase II of C.
burnetii;
 Identifying C. burnetii by PCR or culture in blood or
respiratory material;
 Presence of antibodies against phase I of C. burnetii
(chronic infection).
Until July 2008 a further requirement was a clinical
presentation matching acute Q-fever. As of July 2008,
this was refined and patients meeting the Dutch notifica-
tion criteria had to have at least fever, pneumonia or
hepatitis [28].
Patients diagnosed with Q-fever in 2010 and 2011 in
the Netherlands, who were at least 18 years of age and
fulfilled the Dutch notification criteria of Q-fever, were
eligible for this prospective cohort. The notification cri-
teria since 2010 include also an onset of illness within
Q-fever cohort
meeting the Dutch notification criteria
Onset of illness in 2007-2008
N= roughly 400
Onset of illness in 2010-2011
N=337
Questionnaires:
NCSI at 12-26 months (Morroy et al. 2011)
NCSI at 48 months
Questionnaires:
NCSI at 3,12,18 and 24 months
SF-36 at 3, 6, 9, 12, 18 and 24 months
Reference groups
Healthy controls
N=130
Legionnaires’ 
disease (2010)
N=190
Questionnaires:
NCSI 
SF-36
Questionnaires:
NCSI at 12 months
SF-36 at 12 months
Q-fever with a-specific 
symptoms (2007-2009)
N=roughly 180
Questionnaire:
NCSI 4 years after diagnosis
Figure 1 Explanation of the cohorts and reference groups and the timing of the questionnaires used.
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the previous 90 days. Eligible patients were informed
about the study by the Municipal Health Service and
after having received written consent, patients were
included in the study.
Healthy controls
A control group consisting of healthy participants was
formed by recruiting persons via advertisements in local
newspapers in the city of Nijmegen area. The healthy
controls were age-matched to the group of Q-fever
patients and were asked to visit Radboud University
Nijmegen Medical Centre, University Centre for Chronic
Diseases Dekkerswald, where they completed electronic
questionnaires (the NCSI and SF-36). The lung function
of healthy controls was also tested, so that persons with
an undiagnosed underlying illness that could affect their
health status could be excluded.
Patients with Legionnaires’ disease
Patients diagnosed with Legionnaires’ disease according
to the Dutch notification criteria and an onset of illness
in 2010 were eligible to participate in this study. The
Dutch notification criteria contain a case definition of an
infection confirmed by at least one but preferably two of
the following laboratory diagnostic tests:
 Isolation of Legionella-species from respiratory
secretions of blood;
 Identification of the L. pneumophila-antigen in urine
either by radio-immuno-assay or enzyme linked
immunosorbent assay or immunochromatographic
assay;
 Identification of the Legionella-species by PCR in
clinical material;
 Identification of a significant titre of IgM-antibodies
against L. pneumophila by ELISA;
 Identification of a significant titre elevation of
antibodies against L. pneumophila.
Further requirements are matching clinical symptoms,
usually pneumonia [2]. Patients were recruited through
the Municipal Health Services. Of the roughly 400
patients with an onset of illness in 2010, a sub-sample of
these patients were contacted for our study (N = 243).
Persons with a Q-fever infection but a-specific symptoms
The last reference group consists of persons with a Q-fever
infection but a-specific symptoms. Patients who tested
positive for Q-fever and were notified by the laboratory to
the Municipal Health Service, but who did not have symp-
toms fulfilling the Dutch notification criteria (fever, pneu-
monia or hepatitis), were eligible for this study group.
Consent was obtained through the patient’s General
Practitioner.
Data collection
All patients were contacted by postal mail at determined
time intervals after the onsets of illness (Figure 1). They
received an information letter, a consent form and a
questionnaire. Patients were asked to either return the
signed consent form and the questionnaire simultan-
eously, or only the consent form stating that they did
not want to participate. Patients who did not respond
received a reminder by telephone or postal mail. Patients
who returned an incomplete questionnaire were con-
tacted by telephone by a member of the research team.
Only those Q-fever patients who reported severe fa-
tigue and/or a severe impact on their quality of life at
intervals 12 and 18 months after onset of illness were
eligible to participate at intervals 18 and 24 respectively.
Since the onset of illness could not be determined for
persons with a Q-fever infection but a-specific symp-
toms, these persons will be contacted approximately 4
years after their positive serology was confirmed by the
laboratory. Persons with an onset of infection in 2007
and 2008 will be contacted in 2012, persons with an
onset of infection in 2009 will be contacted in 2013.
Questionnaire
Questionnaires were developed for the patients and
reference groups in our study. The first questionnaire
that patients receive collects information on risk factors
for long-term impaired health status and symptoms due
to Q-fever. The risk factors collected include age, smok-
ing behaviour, alcohol consumption, education, Body
Mass Index, pre-existing health problems (e.g. immune
deficiencies, cancer, diabetes) and hospitalisation. Symp-
toms include all health effects that could be caused by
Q-fever. Questions which may change over the course of
the study are repeated in successive questionnaires (e.g.
smoking behaviour, Body Mass Index, hospitalisation
and symptoms). The NCSI and the SF-36 were used to
measure aspects of health status, fatigue and quality of
life. The NCSI [22] was included only every 6 months as
it is longer and has not been tested at short time inter-
vals (Figure 1). The SF-36 used was the official Dutch
translation obtained from Quality Metric, Lincoln RI,
USA. The NCSI and SF-36 were used simultaneously
since they gather information on different domains.
Data analysis
The main outcome measures are the health status, fa-
tigue and quality of life of Q-fever patients at different
intervals. A secondary outcome is the health status of
Q-fever patients compared to the health status of
healthy controls and patients with Legionnaires’ disease.
Data will be analysed using the software SPSS for win-
dows (version 18).
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Discussion
This study is the largest prospective cohort study that fo-
cuses on the long-term health effects of acute Q-fever to
date. It will provide more insight into the short- and long-
term (up to 4 years) health status, fatigue and quality of
life of acute Q-fever patients. By comparing the long-term
health effects to three reference groups (healthy persons,
persons with a similar infectious disease (Legionnaires’
disease) and persons with a Q-fever infection but a-
specific symptoms), a more comprehensive assessment of
disease progression is better presented.
Even though there has been a major decline in the
number of new acute Q-fever patients during the last
few years, the disease still requires attention. A recent
study in the Netherlands suggests that only a fraction
(7.9%) of all Q-fever infections are notified to the public
health authorities [29]. This is caused by a variety of fac-
tors, such as lack of clinical symptoms during the acute
phase of the disease, not seeking medical attention, and
not being tested for Q-fever with a diagnostic laboratory
test. Assuming this percentage, the total number of
infections in the Netherlands between 2007 and 2011
would be about 52000. Apart from the risks that are
posed by chronic Q-fever, roughly 50% of persons that
were diagnosed one or more years ago still suffer from
long-lasting health effects such as severe fatigue or Post
Q-fever Fatigue Syndrome, although the exact numbers are
currently unknown [20,21]. Attention in the Netherlands is
therefore now shifting from limiting the number of
new infections to monitoring the long-term effects of
acute Q-fever and providing support to these patients
[19,29,30].
The findings of our study will be used by general prac-
titioners and medical specialists to plan and organize the
care for new and existing Q-fever patients, especially
those with long-term symptoms. In addition, as a new
Q-fever outbreak could occur in the Netherlands, else-
where in Europe or internationally, it is important to as-
sess and present the long-term health impact of this
zoonotic infection.
Our study started data collection in September 2010 and
will continue until the beginning of 2013. Data analysis will
start in 2013 and results are expected in 2013 and 2014.
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